摘要
SUMO化修饰是一种能够把小反诉样肽SUMO结合到基板上的共价蛋白后翻译修饰。SUMO化修饰与许多生物过程密切相关,包括细胞增殖、分化、衰老、凋亡等。因此,发现SUMO化修饰的失调在肿瘤的发生及不同种类的肿瘤依赖于功能性SUMO化通路不足为奇。SUMO化修饰作为肿瘤中一个治疗性靶点具有研发潜力。本文综述了与基因组稳定性和DNA损伤应答的SUMO化修饰现有的知识进行了综述,我们将进一步讨论SUMO化修饰在肿瘤干细胞中作为合成致死的搭档和关键的信号通路的治疗潜力。
关键词: SUMO化修饰,基因组稳定性,DNA损伤应答,合成致死,肿瘤干细胞
Current Molecular Medicine
Title:Sumoylation Pathway as Potential Therapeutic Targets in Cancer
Volume: 16 Issue: 10
关键词: SUMO化修饰,基因组稳定性,DNA损伤应答,合成致死,肿瘤干细胞
摘要: Sumoylation is a covalent protein posttranslational modification that conjugates the small ubiquitin-like peptide SUMO to substrate. Sumoylation is critically implicated in multiple biological processes, including cell proliferation, differentiation, senescence and apoptosis, etc. Therefore, it is not surprising that dysregulation of sumoylation has been implicated in tumorigenesis and different types of cancer were found to be addicted to functional sumoylation pathway. The potential role for sumoylation as a therapeutic target in caner is emerging. In this review, we summarize current knowledge regarding the involvement of sumoylation in genome stability and DNA damage response. We will further discuss the therapeutic potential of sumoylation as synthetic lethal partner and as a key signaling pathway in cancer stem cells.
Export Options
About this article
Cite this article as:
Sumoylation Pathway as Potential Therapeutic Targets in Cancer, Current Molecular Medicine 2016; 16 (10) . https://dx.doi.org/10.2174/1566524016666161223105201
DOI https://dx.doi.org/10.2174/1566524016666161223105201 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery ABC Transporters as Potential Targets for Modulation of Drug Resistance
Mini-Reviews in Medicinal Chemistry Cholangiocarcinoma Therapeutics: An Update
Current Cancer Drug Targets Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy
Current Molecular Medicine Alteration of Ceramide 1-O-Functionalization as a Promising Approach for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma
Current Cancer Drug Targets Proteomics in Acute Myelogenous Leukaemia (AML): Methodological Strategies and Identification of Protein Targets for Novel Antileukaemic Therapy
Current Drug Targets OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine NADPH Oxidases NOXs and DUOXs as Putative Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry Cutoff Values of D-Dimer and FDP in Plasma for the Diagnosis of Thrombosis
Vascular Disease Prevention (Discontinued) Signal Transduction and Photodynamic Therapy
Current Signal Transduction Therapy Laccases in Pharmaceutical Chemistry: A Comprehensive Appraisal
Mini-Reviews in Organic Chemistry Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis
Current Molecular Medicine Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design